AVDL News and Press, Avadel Pharmaceuticals plc From 03/10/22

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in participate in a virtual fireside chat at th...

Eight abstracts accepted for poster presentation featuring new data from the Phase 3 REST-ON clinical trial of FT218 and the RESTORE open-label extension/switch study of FT218 in addition to discrete choice experiment results Company supporting Satellite Symposium focused ...

DUBLIN, Ireland, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Douglas Williamson, MBChB, as Chief Medical Officer. “Doug is an outstanding addition...

DUBLIN, Ireland, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat at the 11 th Annual SVB L...

DUBLIN, Ireland, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences i...

Avadel Pharmaceuticals plc (AVDL) Q3 2021 Earnings Conference Call November 8, 2021 08:30 AM ET Company Participants Courtney Turiano - Investor Relations Gregory Divis - Chief Executive Officer Tom McHugh - Chief Financial Officer Richard Kim - Chief Commercial Officer Jennifer Gudeman - Vic...

The shares of Avadel Pharmaceuticals (AVDL +6.8%) have reached a 52-week high after the company reported better than expected financials for Q3 2021. Despite a delay in the FDA review of its narcolepsy candidate, CEO Greg Divis said that Avadel (NASDAQ:AVDL) was preparing for its launch ...

Avadel Pharmaceuticals (NASDAQ:AVDL): Q3 GAAP EPS of -$0.38 beats by $0.01. Cash, cash equivalents and marketable securities were $181.1M as September 30, 2021 Shares -0.67% PM. Press Release For further details see: Avadel Pharmaceuticals EPS beats by $0.01

FDA review of NDA for FT218 ongoing; commercial and launch preparations progressing Presentation of new data from pivotal REST-ON clinical trial at CHEST 2021 demonstrating that treatment with FT218 causes meaningful improvement in cataplexy attacks and measurements of E...

Avadel Pharmaceuticals (NASDAQ:AVDL) is scheduled to announce Q3 earnings results on Friday, November 5th, after market close. The consensus EPS Estimate is -$0.38 (-90.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 0 upward revisions and 3 d...